AstraZeneca's Brilinta Met Primary Endpoint in Phase Three Stroke Trial

Date : 01/27/2020 @ 7:54AM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 44.89  1.04 (2.37%) @ 6:25PM

AstraZeneca's Brilinta Met Primary Endpoint in Phase Three Stroke Trial

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Jan 2020 to Apr 2020

Click Here for more Astrazeneca Charts.

By Adriano Marchese


AstraZeneca PLC (AZN.LN) said Monday that its drug Brilinta met the primary endpoint in a phase three trial for stroke prevention.

The British pharmaceutical major said high-level results from the phase three THALES trial showed Brilinta used twice daily with aspirin reached a statistically significant reduction in the risk of the primary composite endpoint of stroke and death.

"Results of the Phase three THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack," Executive Vice President of BioPharmaceuticals R&D Mene Pangalos said.


Write to Adriano Marchese at


(END) Dow Jones Newswires

January 27, 2020 02:39 ET (07:39 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.